55 patents
Page 2 of 3
Utility
Fumarate analogs and uses thereof
28 Sep 21
Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders.
Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
Filed: 14 Oct 19
Utility
Tyrosine kinase inhibitors
7 Sep 21
Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
Filed: 19 Sep 19
Utility
ACVR2A-specific antibody and method of treatment of muscle atrophy
31 Aug 21
The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same.
Todd M. Kinsella, Ramesh Bhatt, Kristen Baltgalvis
Filed: 27 Mar 18
Utility
Kinase inhibitors and methods for making and using
13 Jul 21
Vanessa Taylor, Yan Chen, Rose Yen
Filed: 12 Feb 20
Utility
TGF-ß inhibitors
1 Jun 21
Marina Gelman, Pingyu Ding, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Jeffrey Clough
Filed: 29 Mar 16
Utility
2,4-pyrimidinediamine compounds and their uses
18 May 21
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
Filed: 19 Jun 19
Utility
RIP1 inhibitory compounds and methods for making and using the same
13 Apr 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Vanessa Taylor, Jiaxin Yu, Esteban Masuda, Ihab Darwish, Yan Chen
Filed: 2 May 19
Utility
Amide compounds and method for making and using
16 Mar 21
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors.
Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
Filed: 2 Aug 19
Utility
AMPK-activating heterocyclic compounds and methods for using the same
9 Mar 21
Dane Goff, Donald Payan, Rajinder Singh, Simon Shaw, David Carroll, Yasumichi Hitoshi
Filed: 25 Jun 19
Utility
Nrf2 activating compounds and uses thereof
9 Mar 21
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 2 Apr 20
Utility
IRAK inhibitors and method for making and using
9 Mar 21
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors.
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Filed: 18 Jun 19
Utility
Prodrugs of Nrf2 activating compounds and uses thereof
12 Jan 21
Aspects of the present disclosure include prodrugs of compounds that activate Nrf2.
Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
Filed: 12 Aug 20
Utility
2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use
7 Dec 20
The invention described herein comprises compounds and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer.
Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Donald Payan, Marina Gelman, Todd Kinsella
Filed: 15 Jan 19
Utility
Tyrosine kinase inhibitors
30 Nov 20
Ihab Darwish, Jiaxin Yu, Rao Kolluri, Sacha Holland
Filed: 28 May 19
Utility
Nrf2 activating compounds and uses thereof
23 Nov 20
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 19 Dec 19
Utility
2,4-pyrimidinediamine compounds and their uses
9 Nov 20
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
Filed: 2 May 19
Utility
TGF-β inhibitorC
2 Nov 20
Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
Filed: 29 Mar 16
Utility
RIP1 inhibitory compounds and methods for making and using the same
26 Oct 20
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 1 May 19
Utility
Protein kinase C inhibitors and uses thereof
5 Oct 20
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC.
Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan
Filed: 11 Mar 18
Utility
Prodrugs of NRF2 activating compounds and uses thereof
14 Sep 20
Aspects of the present disclosure include prodrugs of compounds that activate Nrf2.
Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
Filed: 13 May 19